Evidence map›Paper›PMID 35109825›Full record

ArticleCancer cell international2022

RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures.

Eva-Maria Packeiser, Leila Taher, Weibo Kong, Mathias Ernst, Julia Beck, Marion Hewicker-Trautwein, Bertram Brenig, Ekkehard Schütz, Hugo Murua Escobar, Ingo Nolte

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Eva-Maria PackeiserSmall Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany.
Leila TaherInstitute of Biomedical Informatics, Graz University of Technology, Graz, Austria.
Weibo KongSmall Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany.
Mathias ErnstDivision of Bioinformatics, Department of Biology, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Julia BeckChronix Biomedical, Göttingen, Germany.
Marion Hewicker-TrautweinDepartment of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany.
Bertram BrenigUniversity of Göttingen, Institute of Veterinary Medicine, Göttingen, Germany.
Ekkehard SchützChronix Biomedical, Göttingen, Germany.
Hugo Murua Escobar *Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany. hugo.murua.escobar@med.uni-rostock.de.
Ingo Nolte *Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany. ingo.nolte@tiho-hannover.de.ORCID http://orcid.org/0000-0003-4577-3739
University of Veterinary Medicine Hannover, Foundation · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCanine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) are typically characterized by metastasis and chemoresistance. Cell lines are important model systems for developing new therapeutic strategies. However, as they adapt to culturing conditions and undergo clonal selection, they can diverge from the tissue from which they were originally derived. Therefore, a comprehensive characterization of cell lines and their original tissues is paramount.

methodsThis study compared the transcriptomes of nine canine cell lines derived from PAC, PAC metastasis and TCC to their respective original primary tumor or metastasis tissues. Special interests were laid on cell culture-related differences, epithelial to mesenchymal transition (EMT), the prostate and bladder cancer pathways, therapeutic targets in the PI3K-AKT signaling pathway and genes correlated with chemoresistance towards doxorubicin and carboplatin.

resultsIndependent analyses for PAC, PAC metastasis and TCC revealed 1743, 3941 and 463 genes, respectively, differentially expressed in the cell lines relative to their original tissues (DEGs). While genes associated with tumor microenvironment were mostly downregulated in the cell lines, patient-specific EMT features were conserved. Furthermore, examination of the prostate and bladder cancer pathways revealed extensive concordance between cell lines and tissues. Interestingly, all cell lines preserved downstream PI3K-AKT signaling, but each featured a unique therapeutic target signature. Additionally, resistance towards doxorubicin was associated with G2/M cell cycle transition and cell membrane biosynthesis, while carboplatin resistance correlated with histone, m- and tRNA processing.

conclusionComparative whole-transcriptome profiling of cell lines and their original tissues identifies models with conserved therapeutic target expression. Moreover, it is useful for selecting suitable negative controls, i.e., cell lines lacking therapeutic target expression, increasing the transfer efficiency from in vitro to primary neoplasias for new therapeutic protocols. In summary, the dataset presented here constitutes a rich resource for canine prostate and bladder cancer research.

Indexed as

Bladder cancerCell lineDogGene expressionIn vitro modelMetastasisProstate cancerTargeted therapyTCC

Identifiers

PMID35109825
PMCPMC8812184
OpenAlexW4210795204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.